Impact of an Assay That Enables Rapid Determination of Staphylococcus Species and Their Drug Susceptibility on the Treatment of Patients with Positive Blood Culture Results
The DOI matches its OpenAlex record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine whether an earlier determination of staphylococcal species and their antibiotic susceptibility decreases unnecessary antistaphylococcal treatment and/or facilitates earlier appropriate treatment. METHODS: We used the Xpert MRSA/SA BC system (Cepheid) for immediate determination of species and their drug susceptibility in patients whose blood cultures revealed gram-positive cocci in clusters. We compared the treatment of patients whose physicians received early notification of these results (group 1) with the treatment of patients in a historical cohort with delayed reporting after traditional microbiological studies (group 2). Outcomes were analyzed according to whether blood culture was positive for Staphylococcus species other than S. aureus, methicillin-susceptible S. aureus (MSSA), or methicillin-resistant S. aureus (MRSA) and whether the drugs used were appropriate for methicillin-susceptible or methicillin-resistant staphylococci (hereafter referred to as "MSS drug" or "MRS drug" therapy, respectively). RESULTS: There were 44 (76%) of 58 patients with bacteremia due to Staphylococcus species other than S. aureus in group 1 and 58 (55%) of 106 patients with bacteremia due to Staphylococcus species other than S. aureus in group 2 who received no antistaphylococcal antibiotics (P < .01). Five (6%) of 89 patients in group 1 and 31 (25%) of 123 patients in group 2 received 0-168 hours (0-7 days) of MRS drug therapy (P < .01). Among patients with MSSA bacteremia, the mean time to initiation of appropriate therapy was 5.2 hours in group 1 and 49.8 hours in group 2 (P = .007). Excluding patients who received MRS drug therapy for unrelated conditions, the mean duration of treatment was 19.7 hours in group 1 and 80.7 hours in group 2 (P = .003). Six (50%) of the 12 patients in group 1 and 39 (81%) of the 48 patients in group 2 received MRS drug therapy for MSSA bacteremia (P = .025). Time to initiation of therapy for MRSA bacteremia did not differ between groups. CONCLUSIONS: The use of an assay with rapid results reduced the use of antistaphylococcal therapy among patients who did not have S. aureus bacteremia; it also decreased the use of MRS drug therapy and led to earlier appropriate therapy among patients with MSSA bacteremia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gómez, J., García-Vázquez, E., Baños, R., Canteras, M., Ruiz, J., Baños, V., Herrero, J. A., & Valdés, M. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0272-x · Cited by 81
Fang, C.-T., Shau, W.-Y., Hsueh, P.-R., Chen, Y.-C., Wang, J.-T., Hung, C.-C., Huang, L. Y. L., & Chang, S.-C. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl006 · Cited by 53
Cited by
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
Banerjee, R., Teng, C. B., Cunningham, S. A., Ihde, S. M., Steckelberg, J. M., Moriarty, J. P., Shah, N. D., Mandrekar, J. N., & Patel, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ447 · Cited by 570
“However, these studies were limited by their retrospective designs, use of historical controls [5, 6, 10, 22], lack of randomization, and failure to match subjects by severity of illness [7].”
BackgroundBuehler, S. S., Madison, B., Snyder, S. R., Derzon, J. H., Cornish, N. E., Saubolle, M. A., Weissfeld, A. S., Weinstein, M. P., Liebow, E. B., & Wolk, D. M. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00053-14 · Cited by 298
Maurer, F. P., Christner, M., Hentschke, M., & Rohde, H. (2017) · Infectious Disease Reports · doi:10.4081/idr.2017.6839 · Cited by 169
The Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia
McConeghy, K. W., Bleasdale, S. C., & Rodvold, K. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit560 · Cited by 90
Metadata
- Authors
- Parta, M., Goebel, M. C., Thomas, J., Matloobi, M., Stager, C. E., & Musher, D. M.
- Venue
- Infection Control and Hospital Epidemiology
- Publisher
- Cambridge University Press
- Published
- 2010-08-23
- Volume
- 31
- Issue
- 10
- Pages
- 1043-1048
- ISSN
- 0899-823X (ISSN-L)
- OpenAlex
- W2059984886
- Cited by
- 94
- References
- 2
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.